Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Experimental cancer treatments Stories

2014-01-08 12:28:55

SYDNEY, Jan. 8, 2014 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) can report that the 54(th) late stage melanoma patient has been injected with CAVATAK(TM), thus achieving the major milestone of target enrolment in the US Phase 2 CALM trial. The Phase 2 trial is a single arm study being conducted at 11 US cancer clinics to investigate the safety and efficacy of intratumoral CAVATAK(TM) (Coxsackievirus A21) in patients with late stage malignant melanoma. Dr. Malcolm...

2014-01-06 08:27:53

WORCESTER, Mass. and TORONTO, Jan. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A previously released positive interim analysis showed a strong trend toward reduced...

2013-12-16 08:26:26

Significant Differences In Technology, Trials and Company Positioning Described BETHESDA, Md., Dec. 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today responded to inquiries from shareholders and investors about differences between NW Bio's technology, products and clinical trials and those of a Competitor who recently announced the results of a...

2013-12-13 08:24:57

Combined Safety and Efficacy Results with ThermoDox® plus Hyperthermia for Recurrent Breast Cancer at the Chest Wall LAWRENCEVILLE, N.J., Dec.13, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of the combined clinical study results from the Company's Phase I DIGNITY study and the Duke University sponsored Phase I trial of ThermoDox® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall...

2013-11-18 16:29:13

THOUSAND OAKS, Calif., Nov. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced interim overall survival (OS) results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). Results will be presented today during an oral session at the 2013 Society for Melanoma Research (SMR) Congress, in Philadelphia. At a predefined interim analysis...

2013-11-18 12:29:32

Recognition marks significant industry honor for Genelux proprietary vaccinia-based platform technology SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company's lead product candidate, GL-ONC1, has been selected by Elsevier Business Intelligence as one of its 2013 "Top 10 Oncology Projects to Watch." Genelux will present its vaccinia-based proprietary platform technology at the Elsevier...

2013-11-18 08:30:23

Primary Efficacy Analysis Initiated for Phase II Study of Novel Immunotherapeutic WORCESTER, Mass. and TORONTO, Nov. 18, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary,...

2013-11-08 08:27:45

SEATTLE, Nov. 8, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of preliminary results from an ongoing Phase 1 trial of ONT-10, a therapeutic vaccine targeting the tumor-associated antigen MUC1, at the Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland. The trial is a first-in-man dose escalation trial in patients with advanced, previously treated malignancies of types associated with the expression of MUC1....

2013-11-05 08:35:00

SYDNEY, Nov. 5, 2013 /PRNewswire/ -- UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15(th) World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer...

2013-10-22 08:31:54

CALGARY, Oct. 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster presentation covering progression free survival (PFS) and final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021), is being made today at the AACR-NCI-EORTC International...